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Summary The possible association between breast cancer and oral contraceptive use before the age of 20 was investigated using Icelandic
population-based information from women born after 1944. The design was a nested case-control study within a cohort, using data on
duration of oral contraceptive use at young ages. The availability of oral contraceptives before the age of 20 has changed dramatically and is
highly dependent on birth years, with 20% and 82% starting before the age of 20 among Icelandic users born in 1945-47 and 1963-67
respectively. The association between total duration of oral contraceptive use and breast cancer was significantly dependent on year of birth.
In women born in 1951-67 (based on 81 cases), the relative risk (RR) associated with use for more than 4 years was 2.0 (95% Cl 1.1-3.7).
The association disappeared when women born in 1945-50 were included (RR 1.1, 95% Cl 0.8-1.6), adding 123 cases. A significant trend of
increased risk with longer duration was present only in the group born after 1950, with RR 0.9, 1.7 and 3.0 for <4 years, >4-8 years and > 8
years of use respectively. The results of this study indicate an association between breast cancer and oral contraceptive use at a young age.
They also stress the importance of distinguishing between groups with different opportunities for exposure at young age.
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Much of the research on the association between oral contracep-
tive use and breast cancer risk has given inconclusive results
(Thomas, 1991; Malone et al, 1993). The paper by the
Collaborative Group on Hormonal Factors in Breast Cancer(1996)
was published as this paper went to press. Oral contraceptives
were introduced around 1960 and were prescribed (initially)
mainly for married women. In Britain, oral contraceptive use early
in life became more common in the early 1970s and in the USA in
the late 1970s (McPherson and Drife, 1986). Differences are to be
expected among other countries, complicating research on the
effects of exposure at a young age because the birth cohorts,
exposed at a young age, have only recently entered the age at
which the risk of breast cancer is high. An association between
oral contraceptive use at a young age and breast cancer would not
be detected in studies including a wide range of birth cohorts
because such studies would include too many women for whom
there was no possibility ofearly exposure.
In recent years, several studies have demonstrated an association
between oral contraceptive use and breast cancer when focusing on
women diagnosed underthe age of45 and/or on young users (Pike et
al, 1981; Meierik et al, 1986; McPherson et al, 1987; Kay and
Hannaford, 1988; Miller etal, 1989; Olsson et al, 1989; UK National
Case-Control Study Group, 1989; WHO Collaborative Study of
Neoplasia and Steroid Contraceptives, 1990; Weinstein et al, 1991;
Wingo et al, 1991; Rookus and van Leeuwen, 1994; Brinton et al,
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1995). This may indicate effects in young users because women
diagnosed under the age of 45 in recent years tend to belong to the
birth cohorts exposed at a young age. However, studies on risk asso-
ciated with early age at first use have also given inconclusive results
(Cancer and Steroid Hormone Study, 1986; Meierik et al, 1986;
Olsson et al, 1989; UK National Case-Control Study Group, 1989;
Paul et al, 1990; Weinstein et al, 1991).
In Iceland, prescription practices have changed markedly since
1960. The age at first use of oral contraceptives has been rapidly
decreasing and now nearly all new users start well before the age
of20, whereas most women born before 1950 started after the age
of20 (Manfredsdottir et al, 1996).
Here, we report a study ofthe effects oforal contraceptive use at
young age on the risk of breast cancer in cohorts of Icelandic
women who had the possibility ofexposure at least from the age of
20. We also report the effects of focusing on birth cohorts with a
successively lower age at exposure. The study population was
Icelandic women born after 1944 who participated in a nationwide
cancer detection programme of the Icelandic Cancer Society. The
design was a nested case-control study within a cohort.
METHODS
Two sources of information were used: the population-based
Icelandic Cancer Registry and the databank of the Cancer
Detection Clinic of the Icelandic Cancer Society. The former
covers all cancer cases diagnosed since 1954 in the Icelandic popu-
lation, totalling around 260 000. The latter contains information
from around 90 000 women participating in the cancer detection
activities ofthe Cancer Society, starting in 1964 (Sigurdsson, 1993;
Tryggvadottir et al, 1994). Record linkage uses the personal identi-
fication number ofthe Icelandic National Roster.
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Table 1 Reproductive and menstrual characteristics of cases and matched
controls, as reported at the first visit to the Clinic, for the total study group
(204 cases, 1183 controls). Median age at interview was 29 years (range
18-43 years)
Number (%)
Cases Controls RRa P-value
Age at menarche (year)
<13 78 (38) 367 (31) 1.0 -
13 69 (34) 420 (36) 0.8 0.12
14+ 57 (28) 396 (33) 0.7 0.05
Parous
Yes 175 (86) 1023 (86) 1.0 -
No 29(14) 160 (14) 1.2 0.53
Age at first childbirth
<20 55 (27) 329 (28) 1.0 -
20-29 113 (55) 682 (58) 1.0 0.99
30+ 7 ( 3) 12 ( 1) 3.9 0.01
Number of children
1 47 (23) 289 (24) 1.0 -
2 81 (40) 399 (34) 1.3 0.18
3+ 47 (23) 335 (28) 0.9 0.75
Oral contraceptive use
Never 42 (21) 226 (19) 1.0 -
>0 to <4 years 116 (57) 703 (59) 0.9 0.72
>4to<8years 36 (18) 201 (17) 1.0 0.90
>8years 10( 5) 53( 4) 1.3 0.55
aAll variables included simultaneously.
At the Cancer Detection Clinic, information on various repro-
ductive factors has been gathered by interviewer-administered
questionnaires. Around 95% of Icelandic women born after 1929
have contributed information, most of them on more than one
occasion. Internal comparison between repeated answers indicates
satisfactory reliability ofthe data (Tryggvad6ttir et al, 1994). The
questions have changed with time, however from the beginning
women have provided information regarding age at menarche,
number ofchildren and age at first birth.
A question regarding duration of oral contraceptive use was
added in 1975, but information on the age at use oforal contracep-
tives was not collected and is therefore not available for the women
who participated in this study. However, fordescriptive purposes, a
special survey was conducted by the Cancer Detection Clinic
in 1991 and 1992 on age at first use of oral contraceptives. This
Table 2 Relative risk of breast cancer for oral contraceptive use >4 years vs
< 4 years by birth yearsa, successively excluding earlier years of birth
Birth years Number of RR 95% Cl P-value
cases/controls
Totalstudygroup
1945-67 204/1183 1.1 (0.8-1.6) 0.50
Remainingyears ofbirth
1946-67 180/1039 1.2 (0.8-1.8) 0.25
1947-67 151/865 1.4 (0.9-2.1) 0.14
1948-67 131/761 1.4 (0.9-2.3) 0.13
1949-67 115/669 1.5 (0.9-2.4) 0.11
1950-67 97/567 1.7 (1.0-3.0) 0.06
1951-67 81/472 2.0 (1.1-3.7) 0.02
1952-67 63/372 1.9 (0.9-3.9) 0.08
1953-67 55/323 2.2 (1.0-4.7) 0.05
aAdjusted for age at menarche, parity (yes/no), number of children and age at
first birth.
information was used in the present study to describe changes in
age at first use with descending birth years. A question regarding
brand of oral contraceptives was introduced in 1979, however,
although the response rate formostofthe otherquestions is around
96%, the response rate for this question is only around 72%,
mainly because of problems with recollection. It has been shown
elsewhere that recall ofbrands is not accurate (Coulter et al, 1986).
In this study, the cases were restricted to women born after
1944. Oral contraceptives were used by less than 2% ofwomen of
childbearing age in Iceland before 1964 (Snaedal, 1968), and our
intention was to include only women with a possibility of use at
around the age of 20. The group of cases included all Icelandic
women diagnosed with invasive breast cancer before 1 July 1995
who were born after 1944 and who had given information in the
Cancer Detection Clinic databank between 1975 and 1993, but
before the diagnosis of breast cancer. Information given before
1975 could not be used because of lack of information regarding
duration of oral contraceptive use. The controls were randomly
drawn from the Cancer Detection Clinic databank, matched on
birth year, and year offirst attendance to the Clinic.
As information regarding age at use of oral contraceptives was
not available, we focused on information given at first attendance
to approximate use at young age, the intention being to investigate
the particular contribution of oral contraceptive use at young age.
Table 3 Association between duration of oral contraceptive use and breast cancer for two birth cohorts
Birth cohort Duration of RRa 95% Cl P-value
use (years)
1945-50 0 1 _
(123 cases and 711 controls) <4 1.0 (0.6-1.7) 0.96
>4-8 0.8 (0.4-1.6) 0.52
>8 0.8 (0.3-2.5) 0.75
1951-67b 0 1 -
(81 cases and 472 controls) <4 0.9 (0.4-1.7) 0.69
>4-8 1.7 (0.7-3.8) 0.23
>8 3.0 (0.8-11.0) 0.11
aAdjusted for age at menarche, number of children and age at first birth. bTrend for RR significant (P=0.02) when duration of
oral contraceptive use was included as a continuous variable.
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Figure 1 Oral contraceptive users. The graph gives the cumulative
proportion of women who had started using oral contraception before the
given age for successive birth cohorts
Therefore, in the main analysis, status at first visit was used in the
model, both with respect to information on total duration of oral
contraceptive use and on confounding factors. For cases who had
first attended before 1975, we used first attendance after 1974 and,
for them, controls were drawn from women with a similar pattern
ofattendance.
For estimating the relative risk of breast cancer, conditional
logistic regression was applied, taking into account age at
menarche, parity (yes/no), age at first birth and number of chil-
dren. To investigate the effects ofbirth year on the observed asso-
ciation, an interaction term was included in the model (a
multiplication factor between the variables 'year of birth' and
'duration of oral contraceptive use'). To investigate the effects of
age at diagnosis, a similar interaction term was also included for
this variable.
RESULTS
A total of 236 breast cancer cases born after 1944 had been diag-
nosed in Iceland at the end ofJuly 1995. Ofthose, 95% were iden-
tified in the Detection Clinic databank, ofwhich 204 cases (86% of
total) remained after exclusion of women who had not answered
the questions after 1974 and/or only after diagnosis of breast
cancer. The median age at diagnosis was 40 years (range 27-49
years). As controls, 1183 women were selected, on average 5.8 per
case (range 3-7).
The women in the study were aged between 18 and 43 years at
first visit, with a median age of 29 years. The reproductive and
menstrual characteristics for cases and controls at the time of first
visit are shown in Table 1, along with the relative risk for breast
cancer. Young age at menarche, nulliparity and high age at first
birth were significantly associated with increased breast cancer
risk in this group ofyoung women.
For the whole study group, no association was observed
between duration of oral contraceptive use before first visit and
breast cancer. The effect ofbirth years on the observed association
with use for more than 4 years is shown in Table 2. When succes-
sively eliminating older birth cohorts, the RR increased and for
women born in 1951 and later a significant RR of2.0 was observed
(P=0.02). The interaction term between year ofbirth and duration
of oral contraceptive use entered the model (P=0.04). Table 3
Table 4 Brands of oral contraceptives reported by the participants in the
study
Cases (%) Controls (%)
Cohortbom in 1945-50 n = 24 n = 166
Neogynona 17 29
Eugynonb 38 30
Microgync 12 10
Gynovlard 12
Delpregnine - 10
Other brandsg 21 22
Cohortbom in 1951-67 n=40 n=24
Neogynon 40 31
Eugynon 32 22
Microgyn 15 27
ConIumin' - 5
Other brandsg 12 14
aLevonorgestrelum INN 0.25 mg and Ethinylestradiolum INN 50,ug.
bNorgestrelum INN 0.5 mg and Ethinylestradiolum INN 50,tg.
cLevonorgestrelum INN 0.15 mg and Ethinylestradiolum INN 30 9g.
dNorethisteronum INN, acetat, 3 mg and Ethinylestradiolum INN 50 ,Ig.
eMegestroli acetats NFN 5 mg and Mestranolum NFN 0.1 mg.
'Norethisteronum INN 1 mg and Mestranolum INN 50 ,ug. gOnly brands used
by at least 5% of the group are listed. n = number of answers.
shows the effects of duration of oral contraceptive use when the
birth cohorts 1945-50 and 1951-67 were studied separately. In the
former group, no effect was seen whereas, in the latter group, a
significant trend was present when the total duration oforal contra-
ceptive use was included as a linear continuous variable. The
median age at first attendance was 30 years and 26 years in the
older and younger birth cohort respectively. The upper limit ofage
at diagnosis was 43 years or lower for women born after 1950
compared with 49 years for the total group. An interaction term
including age at diagnosis did not enter the model (P=0.41).
Figure 1 shows that the age at onset of oral contraceptive use in
Iceland has steadily been decreasing for successive birth cohorts.
The numbers are based on 8393 answers to the temporary ques-
tions regarding age at first use from 1991-92. The percentage of
ever users was 90% or similar for all the birth cohorts in Figure 1.
The cumulative percentage of oral contraceptive users who started
before the age of 20 years was 20% and 82% for women born in
1945-47 and 1963-67 respectively. Furthermore, it was 31% and
72% in the birth cohorts 1945-50 and 1951-67 respectively. Ofthe
women in the older cohort, 2% had started oral contraception
before the age of 17, whereas 22% had started before the age of 17
in the younger cohort.
We looked at the information given regarding brands of oral
contraceptives separately for the group born before 1951 and for
the group born in 1951-67. As information on brands had not been
collected before 1979, it was not available for approximately 50%
of the study group who had given answers in 1975-78. This was
more pronounced in the group ofwomen born before 1951, as they
had attended somewhat earlier for the first time. Furthermore, only
around 72% ofthose who were asked remembered what brand they
had used. The information shown in Table 4 is thus based on only
34% of the study group. Neogynon, Eugynon and Microgyn were
reported by 63% of the cases born before 1951 and by 69%
of the controls born in the same years. The same brands
were reported by 85% of the cases born after 1950 and by 79%
ofthe controls.
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DISCUSSION
The age at first use of oral contraceptives has been decreasing
rapidly in Iceland and is tightly associated with birth year for the
cohorts included in this study. A similar trend has also been
observed in other countries because, initially, the practice was to
prescribe oral contraceptives only to married women. The timing
of this trend has differed between countries and could cause
discrepancies between epidemiological studies, assuming that
there is a latent carcinogenic effect oforal contraceptive use before
the age of 20 and no adverse effects of use at higher ages
(McPherson and Drife, 1986). Only studies focusing on women
who were born recently enough to have had the opportunity ofthis
early exposure will have the potential to investigate this associa-
tion. In the present study, the association between total duration of
oral contraceptive use and breast cancer was significantly depen-
dent on year ofbirth. Furthermore, in women born in 1951-67, the
relative risk associated with use for more than 4 years was 2.0
(95% CI 1.1-3.7), whereas the association was no longer apparent
when women born in 1945-50 were included (RR 1.1, 95% CI
0.8-1.6). In the older and younger cohort, 31% and 72% had
started using oral contraception before the age of20 respectively.
Several studies have suggested an increased risk associated
with recent or current use of oral contraceptives (Romieu et al,
1989; WHO Collaborative Study of Neoplasia and Steroid
Contraceptives, 1990; Rookus and van Leeuwen, 1994; Brinton et
al, 1995). This was recently confirmed by the comprehensive
meta-analysis ofthe Collaborative Group on Hormonal Factors in
Breast Cancer (1996). Regrettably, in the present prospective
study, information was not available on recency of use at the
time of diagnosis. It can be argued that, as less than 10% of
Icelandic women over 39 years of age use oral contraceptives
(Manfredsdottir et al, 1996), the women who belonged to the
younger birth cohorts in the present study group were more likely
to be current users at diagnosis than women in the older cohort
because they would tend to be younger at diagnosis. Current use
could thus explain the association with birth year observed in this
study. On the other hand it can be argued that as current users are
more likely to belong to younger birth cohorts, they are also
more likely to have been exposed atyoung age. Therefore, an asso-
ciation with recent birth years might at least partly explain
the findings of the effects of current use in some studies (such
as the WHO Collaborative Study of Neoplasia and Steroid
Contraceptives, 1990).
It was not possible to distinguish between the effects ofthe two
highly correlated variables, use at young age and use before first
pregnancy, as information was not available on the timing of oral
contraceptive use. Median age at first pregnancy was 21 in both
birth cohorts, hence the younger cohort was both more likely
to have used oral contraceptives before first birth and before the
age of 20 than the older cohort. Thus, the observed difference
between the two birth cohorts could equally well be explained by
an association with use before first pregnancy as with use before
the age of20.
Apart from not having information regarding recency ofuse, the
other main weakness ofthe present study was the lack ofinforma-
tion on timing of oral contraceptive use. To compensate for this,
we used information on total duration of oral contraceptive use
given at the women's first visit to the clinic, when the median age
at answer was 29 years, thus approximating use at a young age.
The strength ofthis study lies in the prospective nature ofthe data,
in which the observed association can not be explained by infor-
mation bias, and in the fact that 86% of Icelandic breast cancer
patients born after 1944 were included. Surveillance bias is not a
probable explanation of the association being confined to the
youngerbirth cohort, as pill users in the younger birth cohort were
not likely to be under a better surveillance than those in the older
birth cohort. The confounding factors age at menarche, parity, age
at first birth and number of children were controlled for. The
matching of age and year of answering allowed an uncomplicated
comparison between the cases and the controls with respect to
duration oforal contraceptive use at young age, during a period of
very rapid changes in age at first use. Finally, the potential for
finding a postulated effect in young users was high, because only
women born after 1944 were included in the study group.
Information regarding brands of oral contraceptives was based
on answers from only one third of the group and could, therefore,
only be used for indicating which brands were most prominent.
Over two thirds of those who answered, both in the older and the
younger group, used Neogynon, Eugynon or Microgyn. These are
combination oral contraceptives.
The present findings are in agreement with the hypothesis by
Pike et al (1983) postulating that combination oral contraceptives,
a mixture of oestrogen and progestogen, may stimulate mitotic
activity in the breast and that this may, in young women, coun-
teract the natural protection caused by frequent anovulatory
cycles. Underlying is the assumption that, during the luteal phase
of each regular menstrual cycle, women are more sensitive to
external risk factors because of increased mitotic activity during
this period. It should also be borne in mind thatthe age between 10
and 20 has been shown to be the period when the female breast is
most sensitive to ionizing radiation (Land et al 1994), which might
also apply for other mutagenic agents.
In this study, a significant association was detected between
breast cancer and exposure to oral contraceptives at young age in
women born after 1950, whereas no association was evident in the
older cohorts, and the association was not detectable after mixing
of the younger and the older cohort. The results support the find-
ings in several recent studies of an association between oral
contraceptive use and breast cancer in young women, and they
stress the importance of doing separate analyses on groups with
different possibilities ofexposure at young age.
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